Patents by Inventor Rubén ARTERO ALLEPUZ

Rubén ARTERO ALLEPUZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDES CONJUGATED TO OLEIC ACID AND USES THEREOF
    Publication number: 20230407305
    Abstract: The invention provides oligonucleotide and/or oligonucleotide analogue molecules that are antagonists of a microRNA, preferably antagonists of human microRNAs hsa-miR-23b-3p and hsa-miR-218-5p, that comprise a mixture of phosphorothioate and phosphodiester linkages, and that are conjugated to at least one oleic acid molecule. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2. The present invention further provides compositions comprising said oligonucleotides and/or oligonucleotide analogue molecules and their uses for the treatment and prevention of DM in a subject in need thereof.
    Type: Application
    Filed: May 23, 2023
    Publication date: December 21, 2023
    Inventors: Rubén ARTERO ALLEPUZ, Nerea MORENO CERVERA, Irene GONZÁLEZ MARTÍNEZ, Estefanía CERRO HERREROS, Eric G. MARCUSSON, María Beatriz LLAMUSÍ TROISI
  • Compounds for the treatment of myotonic dystrophy
    Patent number: 10226467
    Abstract: The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 12, 2019
    Assignees: Universitat de Valencia, Institut Quimic de Sarria Cets Fundacio Privada, Institut Univ. de Ciencia I Tecnologia, S.A.
    Inventors: Ruben Artero Allepuz, Josep Castells Boliart, José Ignacio Borrell Bilbao, Beatriz Llamusi Troísi, Ariadna Bargiela Schönbrunn, Piotr Konieczny, Marta Pascual Gilabert, Jordi Teixidó Closa, Roger Estrada Tejedor, Alejandro López González
  • COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY
    Publication number: 20170312285
    Abstract: The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).
    Type: Application
    Filed: November 13, 2015
    Publication date: November 2, 2017
    Inventors: Ruben ARTERO ALLEPUZ, Josep CASTELLS BOLIART, José Ignacio BORRELL BILBAO, Beatriz LLAMUSI TROÍSI, Ariadna BARGIELA SCHÖNBRUNN, Piotr KONIECZNY, Marta PASCUAL GILABERT, Jordi TEIXIDÓ CLOSA, Roger ESTRADA TEJEDOR, Alejandro LÓPEZ GONZÁLEZ
  • CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2
    Publication number: 20170304309
    Abstract: The present invention relates to caffeine for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising caffeine for use in the treatment of myotonic dystrophy type 1 and type 2.
    Type: Application
    Filed: November 13, 2015
    Publication date: October 26, 2017
    Inventors: Ruben ARTERO ALLEPUZ, Josep CASTELLS BOLIART, José Ignacio BORRELL BILBAO, Beatriz LLAMUSI TROÍSI, Ariadna BARGIELA SCHÖNBRUNN, Piotr KONIECZNY, Marta PASCUAL GILABERT, Jordi TEIXIDÓ CLOSA, Roger ESTRADA TEJEDOR, Alejandro LÓPEZ GONZÁLEZ
  • PHENANTHRENE DERIVATIVES FOR USE AS MEDICAMENTS
    Publication number: 20160194274
    Abstract: The present invention refers to phenanthrene derivatives for use as medicaments, mainly in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spinocerebellar Ataxia Type 3, Fragile-X-Associated Tremor/Ataxia Syndrome, Frontotemporal Degeneration/Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia Type 31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents. Therefore, this invention may be included either in the whole pharmaceutical or medical field.
    Type: Application
    Filed: December 13, 2013
    Publication date: July 7, 2016
    Inventors: Irma GARCÍA ALCOVER, Arturo LÓPEZ CATEL, María del Carmen ÁLVAREZ ABRIL, Jose Rubén TORMO BELTRÁN, Manuel PÉREZ ALONSO, Rubén ARTERO ALLEPUZ, Diego Miguel CORTÉS MARTÍNEZ